MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Anavex Life Sciences Corp

Затворен

СекторЗдравеопазване

10.76 6.96

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

10.45

Максимум

10.94

Ключови измерители

By Trading Economics

Приходи

915K

-11M

Служители

42

EBITDA

106K

-12M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+169.63% upside

Дивиденти

By Dow Jones

Следващи печалби

5.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

69M

797M

Предишно отваряне

3.8

Предишно затваряне

10.76

Настроения в новините

By Acuity

18%

82%

22 / 375 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.07.2025 г., 23:45 ч. UTC

Придобивния, сливания и поглъщания

Orix Corp. USA to Buy Majority Stake in Hilco Global >8591.TO

3.07.2025 г., 23:42 ч. UTC

Пазарно говорене

Gold Edges Higher Amid U.S. Fiscal-Deficit Concerns -- Market Talk

3.07.2025 г., 23:41 ч. UTC

Пазарно говорене

Nikkei May Rise After Solid U.S. Jobs Data -- Market Talk

3.07.2025 г., 23:41 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

3.07.2025 г., 23:15 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Beach Energy Could Smooth Path to Santos Takeover Approval -- Market Talk

3.07.2025 г., 22:59 ч. UTC

Пазарно говорене

Uranium Market About to Enter Lull -- Market Talk

3.07.2025 г., 22:58 ч. UTC

Пазарно говорене

Value Emerging in Diversified Miners Despite Headwinds -- Market Talk

3.07.2025 г., 22:47 ч. UTC

Пазарно говорене

Australian Household Spending Numbers Key Ahead of RBA Meeting -- Market Talk

3.07.2025 г., 22:21 ч. UTC

Печалби

This Summer's Big TV Hit Brings Back Soap Opera Memories -- Barrons.com

3.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

3.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

3.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

3.07.2025 г., 20:41 ч. UTC

Пазарно говорене

KKR Seen As Benefiting From Stabilizing Markets -- Market Talk

3.07.2025 г., 20:41 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

3.07.2025 г., 19:28 ч. UTC

Пазарно говорене

Oil Gives Back Some Gains With OPEC+ in View -- Market Talk

3.07.2025 г., 19:03 ч. UTC

Пазарно говорене

U.S. Natural Gas Retreats Ahead of Long Weekend -- Market Talk

3.07.2025 г., 18:34 ч. UTC

Пазарно говорене

Gold Has Winning Week, But Down Day -- Market Talk

3.07.2025 г., 18:18 ч. UTC

Пазарно говорене

Anticipation for Trump Address Gives Grain Traders Optimism -- Market Talk

3.07.2025 г., 18:06 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

3.07.2025 г., 18:06 ч. UTC

Пазарно говорене

Brazilian Stocks, Bonds Expected to Benefit From Benign Macro Trends -- Market Talk

3.07.2025 г., 17:27 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Continues to Slide -- Market Talk

3.07.2025 г., 16:55 ч. UTC

Печалби

Travel Stocks Could Offer Investors a Glorious -2-

3.07.2025 г., 16:55 ч. UTC

Печалби

Travel Stocks Could Offer Investors a Glorious Trip, This Analyst Says -- Barrons.com

3.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Correction to Health Care Roundup: Market Talk

3.07.2025 г., 16:15 ч. UTC

Пазарно говорене

Oil Futures Lose Ground in Choppy Pre-Holiday Trade -- Market Talk

3.07.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

3.07.2025 г., 16:05 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

3.07.2025 г., 16:05 ч. UTC

Пазарно говорене

Gold Futures Fall Following Jobs Report -- Market Talk

3.07.2025 г., 15:47 ч. UTC

Печалби

Honeywell Stock Is on a Roll. It Looks Ready to Break Out. -- Barrons.com

3.07.2025 г., 15:36 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Why It's Time to Buy This Rocks and Cement Spinoff Stock You've Probably Never Heard Of -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

169.63% нагоре

12-месечна прогноза

Среден 28.5 USD  169.63%

Висок 42 USD

Нисък 15 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

2

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Neutral Evidence

Настроение

By Acuity

22 / 375 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.